<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AZELASTINE HYDROCHLORIDE- azelastine hydrochloride solution/ drops </strong><br>Wallace Pharmaceuticals Inc.<br></p></div>
<h1><span class="Bold">Azelastine Hydrochloride<br>Ophthalmic Solution, 0.5%<br></span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="befc-0002a5d5c51b"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Azelastine Hydrochloride Ophthalmic Solution, 0.5% is a sterile ophthalmic solution containing azelastine hydrochloride, a relatively selective H<span class="Sub">1</span>-receptor antagonist for topical administration to the eyes. Azelastine hydrochloride is a white crystalline powder with a molecular weight of 418.37. Azelastine hydrochloride is sparingly soluble in water, methanol and propylene glycol, and slightly soluble in ethanol, octanol, and glycerine. Azelastine hydrochloride is a racemic mixture with a melting point of 225°C. The chemical name for azelastine hydrochloride is (±)-1-(2H)-phthalazinone,4-[(4-chlorophenyl) methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride and is represented by the following chemical structure: </p>
<div class="Figure"><img alt="Chemical Structure of Azelastine Hydrochloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f2f72f86-c1c8-11df-851a-0800200c9a66&amp;name=azelastine-hydrochloride-figure-1.jpg"></div>
<p>Empirical chemical structure: C<span class="Sub">22</span>H<span class="Sub">24</span>ClN<span class="Sub">3</span>O•HCl </p>
<p>Each mL of Azelastine Hydrochloride Ophthalmic Solution contains: <span class="Bold">Active: </span>0.5 mg azelastine hydrochloride, equivalent to 0.457 mg of azelastine base; <span class="Bold">Preservative: </span>0.125 mg benzalkonium chloride; <span class="Bold">Inactives: </span>disodium edetate dihydrate, hypromellose, sorbitol solution, sodium hydroxide and water for injection. It has a pH of approximately 5.0 to 6.5 and an osmolarity of approximately 271 to 312 mOsmol/L.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="a071-0002a5d5c51b"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Azelastine hydrochloride is a relatively selective histamine H<span class="Sub">1</span> antagonist and an inhibitor of the release of histamine and other mediators from cells (e.g. mast cells) involved in the allergic response. Based on <span class="Italics">in-vitro</span> studies using human cell lines, inhibition of other mediators involved in <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (e.g. leukotrienes and PAF) has been demonstrated with azelastine hydrochloride. Decreased chemotaxis and activation of eosinophils has also been demonstrated.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="bd31-0002a5d5c51b"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">Absorption of azelastine following ocular administration was relatively low. A study in symptomatic patients receiving one drop of Azelastine Hydrochloride Ophthalmic Solution in each eye two to four times a day (0.06 to 0.12 mg azelastine hydrochloride) demonstrated plasma concentrations of azelastine hydrochloride to generally be between 0.02 and 0.25 ng/mL after 56 days of treatment. Three of nineteen patients had quantifiable amounts of N-desmethylazelastine that ranged from 0.25–0.87 ng/mL at Day 56.</p>
<p>Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively. Approximately 75% of an oral dose of radiolabeled azelastine hydrochloride was excreted in the feces with less than 10% as unchanged azelastine. Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system. <span class="Italics">In-vitro</span> studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="a78e-0002a5d5c51b"></a><a name="section-2.2"></a><p></p>
<h2>Clinical Trials</h2>
<p class="First">In a conjunctival antigen challenge study, Azelastine Hydrochloride Ophthalmic Solution  was more effective than its vehicle in preventing <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>. Azelastine Hydrochloride Ophthalmic Solution had a rapid (within 3 minutes) onset of effect and a duration of effect of approximately 8 hours for the prevention of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
<p>In environmental studies, adult and pediatric patients with seasonal <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span> were treated with Azelastine Hydrochloride Ophthalmic Solution for two to eight weeks. In these studies, Azelastine Hydrochloride Ophthalmic Solution was more effective than its vehicle in relieving <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="be46-0002a5d5c51b"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Azelastine Hydrochloride Ophthalmic Solution is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the eye associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ab63-0002a5d5c51b"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Azelastine Hydrochloride Ophthalmic Solution is contraindicated in persons with known or suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="b5f3-0002a5d5c51b"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Azelastine Hydrochloride Ophthalmic Solution is for ocular use only and not for injection or oral use. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ca1ca620-59c8-11de"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34076-0">
<a name="b4f7-0002a5d5c51b"></a><a name="section-6.1"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">To prevent contaminating the dropper tip and solution, care should be taken not to touch any surface, the eyelids, or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. This product is sterile when packaged. </p>
<p>Patients should be advised not to wear a contact lens if their eye is red. Azelastine Hydrochloride Ophthalmic Solution should not be used to treat contact lens related irritation. The preservative in Azelastine Hydrochloride Ophthalmic Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and <span class="Bold">whose eyes are not red</span>, should be instructed to wait at least ten minutes after instilling Azelastine Hydrochloride Ophthalmic Solution before they insert their contact lenses. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="b812-0002a5d5c51b"></a><a name="section-6.2"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Azelastine hydrochloride administered orally for 24 months was not carcinogenic in rats and mice at doses up to 30 mg/kg/day and 25 mg/kg/day, respectively. Based on a 30 µL drop size, these doses were approximately 25,000 and 21,000 times higher than the maximum recommended ocular human use level of 0.001 mg/kg/day for a 50 kg adult. </p>
<p>Azelastine hydrochloride showed no genotoxic effects in the Ames test, DNA repair test, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay, mouse micronucleus test, or chromosomal aberration test in rat bone marrow. Reproduction and fertility studies in rats showed no effects on male or female fertility at oral doses of up to 25,000 times the maximum recommended ocular human use level. At 68.6 mg/kg/day (57,000 times the maximum recommended ocular human use level), the duration of the estrous cycle was prolonged and copulatory activity and the number of pregnancies were decreased. The numbers of corpora lutea and implantations were decreased; however, the implantation ratio was not affected. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="b19abbe0-59c9-11dejt-preg"></a><a name="section-6.3"></a><p></p>
<h2>Pregnancy:</h2>
<p class="First">Teratogenic Effects:   Pregnancy Category C. Azelastine hydrochloride has been shown to be embryotoxic, fetotoxic, and teratogenic (external and skeletal abnormalities) in mice at an oral dose of 68.6 mg/kg/day (57,000 times the recommended ocular human use level). At an oral dose of 30 mg/kg/day (25,000 times the recommended ocular human use level), delayed ossification (undeveloped metacarpus) and the incidence of 14<span class="Sup">th</span> rib were increased in rats. At 68.6 mg/kg/day (57,000 times the maximum recommended ocular human use level) azelastine hydrochloride caused resorption and fetotoxic effects in rats. The relevance to humans of these skeletal findings noted at only high drug exposure levels is unknown.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Azelastine Hydrochloride Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="bd0c-0002a5d5c51bjt-nm"></a><a name="section-6.4"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether azelastine hydrochloride is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Azelastine Hydrochloride Ophthalmic Solution is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="cc79e520-59ca-11dejt-ped"></a><a name="section-6.5"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 3 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ef50a840-59ca-11dejt-ger"></a><a name="section-6.6"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger adult patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a421-0002a5d5c51bjt-ar"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Wallace Pharmaceuticals Inc. at 1-800-619-6344 or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics">www.fda.gov/medwatch.</span></p>
<p>In controlled multiple-dose studies where patients were treated for up to 56 days, the most frequently reported adverse reactions were transient eye burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> (approximately 30%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> (approximately 15%) and bitter taste (approximately 10%). The occurrence of these events was generally mild. </p>
<p>The following events were reported in 1–10% of patients: <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> and temporary blurring. Some of these events were similar to the underlying disease being studied. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ae57-0002a5d5c51bjt-dos-ad"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one drop instilled into each affected eye twice a day.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="b34b-0002a5d5c51bjt-how-sup"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Azelastine Hydrochloride Ophthalmic Solution, 0.05% is supplied as follows:<br>6 mL (NDC# 51525-7815-6) solution in a translucent 10 mL HDPE container with a LDPE dropper tip and a white HDPE screw cap.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="a49c-0002a5d5c51bjt-stor"></a><a name="section-9.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store UPRIGHT between 2° and 25°C (36° and 77°F).</p>
<p><span class="Bold">Rx Only</span></p>
<p>Manufactured by:<br>
									Patheon UK Ltd.<br>
									Swindon, United Kingdom<br></p>
<p>For:</p>
<p><span class="Bold">Wallace Pharmaceuticals Inc.<br>									
									Somerset, NJ 08873-4120</span></p>
<p><span class="Bold">Wallace Pharmaceuticals</span></p>
<p>Made in United Kingdom</p>
<p>IN-7815-01                          Rev. 5/10</p>
<p>OTE 91560</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="c5348fc0-5a85-11dejt-label-5"></a><a name="section-10"></a><p></p>
<h1>Package Label - Principal Display Panel – 6 mL-fill</h1>
<p class="First"><span class="Bold">NDC 51525-7815-6</span></p>
<p>Azelastine Hydrochloride<br>Ophthalmic Solution, 0.05%</p>
<p><span class="Bold">Rx Only     6 mL – Sterile</span></p>
<p><span class="Bold">Usual dosage: </span>1 drop per affected eye(s) twice daily. <br>See package insert for full Prescribing Information. <br>STORE UPRIGHT between 2° and 25°C (36° and 77°F).</p>
<p><br>Mfd by: Patheon UK Ltd. Swindon, United Kingdom</p>
<p>For:<br>
							Wallace Pharmaceuticals Inc.<br>							
							Somerset, NJ 08873-4120<br><br>Wallace Pharmaceuticals</p>
<p>LB-781506-01</p>
<p>Rev. 5/10</p>
<p>Made in United Kingdom</p>
<p>OTD 91080</p>
<p>Exp. Date<br>Lot No.</p>
<p><img alt="6 mL Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f2f72f86-c1c8-11df-851a-0800200c9a66&amp;name=azelastine-hydrochloride-figure-2.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AZELASTINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">azelastine hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51525-7815</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAOCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AZELASTINE HYDROCHLORIDE</strong> (AZELASTINE) </td>
<td class="formItem">AZELASTINE HYDROCHLORIDE</td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">125 ug  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51525-7815-6</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">6 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA021127</td>
<td class="formItem">10/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Wallace Pharmaceuticals Inc.
							(962531955)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>edbf877a-80ef-412b-9d77-cc67d2850fb3</div>
<div>Set id: f2f72f86-c1c8-11df-851a-0800200c9a66</div>
<div>Version: 2</div>
<div>Effective Time: 20140415</div>
</div>
</div> <div class="DistributorName">Wallace Pharmaceuticals Inc.</div></p>
</body></html>
